EPISODE · Nov 21, 2022 · 2H 12M
#91: Marco Schmidt - AI in Drug Discovery and Drug Development: What You Need to Know
from Beginner's Mind · host Christian Soschner
What is the Role of Artificial Intelligence in Drug Development and Drug Discovery?⭐ In this episode, we talk about:Deep Mind’s AlphafoldInvesting in Life Science companiesThe State of AI in Drug Development and Drug DiscoveryHow does GDPR limit the development of AI in Drug DiscoveryThe Human Genome and AIToday’s speaker is Marco Schmidt, CSO of Biotx.aiMarco had an exceptional academic career. He won the best PhD of the year award in Chemistry in his home country Germany and then went on to do a Post-Doc at the University of Cambridge.⭐ EPISODE Links:Marco Schmidt on Linkedin Youtube 📖 Quotes:(24:45) “Eroom's law is the observation that drug discovery is becoming slower and more expensive over time”(56:05) “We need more data”(58:13) “Biobanks provide the infrastructure that we really need in the future”(01:16:39) “Prediction Models of Type 2 Diabetes Have 99% Accuracy”(01:17:50) “There is no longevity gene. There are shortevity genes.”(01:53:45) “We are living in fantastic times” ⏰ Timestamps:(00:00) Kick Off and Intro(06:15) Deep Mind’s Alphafold(07:06) Background to Marco Schmidt and Biotx.ai (12:00) Business Model in AI for Drug Development – from Service Provider to Developer(13:15) Basic Definition of Drug Discovery and Drug Development for the Listeners of the Episode(17:20) For Retail Investors who have an eye on investing in public drug development companies: What is a Ligand?(20:09) Why is Drug Discovery Expensive and Lengthy?(23:30) Success and Failure Rate in Drug Development(24:30) What is erooms Law?(27:25) What is the right place for innovation? Startups or Big Corporations?(30:00) The Value Chain in the Pharma Industry – From Research to Marketed Products.(34:00) Investing in Life Science Companies(50:15) Why is Artificial Intelligence an Attractive Area?Speaker and Company(55:00) The State of AI in Drug Development and Drug Discovery – What is Science and What is Still Fiction.(58:00) Accessibility of Data – Is this the bottleneck in Artificial Intelligence Based Drug Discovery?(01:10:00) What would change in Drug Development if scientists could access healthy population data?(01:12:30) Prediction Models for Cancer, Alzheimer, and other diseases(01:16:00) Understanding the progression of diseases and the role lifestyle plays in AI(01:19:00) How does GDPR limit the development of AI in Drug Discovery(01:24:00) Data Curation in AI(01:28:45) Is Capital a Limiting Factor?(01:34:26) The Human Genome and AI(01:40:00) Is it possible to simulate the entire drug development process from lab to market?(01:46:00) Service Offerings of biotx.ai(01:51:30) How can AI help select the right patients?(01:59:00) Synthetic clinical trials(02:01:00) The Role of Excel in Machine Learning📚 Book Mentions:Drug Discovery and Drug DevelopmentThe Power Law Send us Fan Mail Join Christian Soschner for expert coaching. 50% Off - With 35+ years in deep tech, startups/scaleups, and public companies, Christian offers power video sessions. Elevate strategy, execution, and leadership. Book Now.Support the showJoin the Podcast Newsletter: Link
What this episode covers
What is the Role of Artificial Intelligence in Drug Development and Drug Discovery? ⭐ In this episode, we talk about: Deep Mind’s AlphafoldInvesting in Life Science companiesThe State of AI in Drug Development and Drug DiscoveryHow does GDPR limit the development of AI in Drug DiscoveryThe Human Genome and AIToday’s speaker is Marco Schmidt, CSO of Biotx.ai Marco had an exceptional academic career. He won the best PhD of the year award in Chemistry in his home country Germany and then went o...
NOW PLAYING
#91: Marco Schmidt - AI in Drug Discovery and Drug Development: What You Need to Know
No transcript for this episode yet
Similar Episodes
No similar episodes found.